Abvc Biopharma Inc (ABVC)

$0.54 -0.01 (-2.01%)
Market Cap 7.15M
Revenue (ttm) 150,000.00
Net Income (ttm) -10.52M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -7,013.33%
Debt to Equity Ratio 0.00
Volume 74,900
Avg Vol 231,350
Day's Range N/A - N/A
Shares Out 12.98M
Stochastic %K 21%
Beta 0.70
Analysts Strong Buy
Price Target $20.20

Latest News on ABVC

ABVC BioPharma Secures $200,000 in First Cash Licensing Payment From Oncology Products Partner, Totaling $546,000 From Three Partners

Dec 11, 2024, 6:30 AM EST - 5 weeks ago

ABVC BioPharma Secures $200,000 in First Cash Licensing Payment From Oncology Products Partner, Totaling $546,000 From Three Partners

ABVC BioPharma Receives $50,000 in Incremental Licensing Fees, Boosting Total Payments to $346,000 From Its Three Strategic Partners

Oct 22, 2024, 8:45 AM EDT - 3 months ago

ABVC BioPharma Receives $50,000 in Incremental Licensing Fees, Boosting Total Payments to $346,000 From Its Three Strategic Partners

ABVC BioPharma, Inc. Reports Strong Q2 2024 Financial Results and Strategic Achievements

Aug 15, 2024, 7:30 AM EDT - 5 months ago

ABVC BioPharma, Inc. Reports Strong Q2 2024 Financial Results and Strategic Achievements

AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per Share

Apr 18, 2024, 9:25 AM EDT - 9 months ago

AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per Share

ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M

Apr 17, 2024, 9:00 AM EDT - 9 months ago

ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M

ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M

Apr 10, 2024, 8:30 AM EDT - 10 months ago

ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M

ABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60M

Mar 26, 2024, 8:30 AM EDT - 10 months ago

ABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60M

ABVC BioPharma, Inc. CEO Selected as 2024 Top 10 CEO in CEO Insights Asia Magazine

Mar 19, 2024, 8:30 AM EDT - 10 months ago

ABVC BioPharma, Inc. CEO Selected as 2024 Top 10 CEO in CEO Insights Asia Magazine

ABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business Update

Mar 14, 2024, 9:30 AM EDT - 11 months ago

ABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business Update

ABVC BioPharma Executes a Definitive Agreement to Receive License Fees of $3M and Royalties of 2% on Future Revenues

Feb 15, 2024, 8:30 AM EST - 1 year ago

ABVC BioPharma Executes a Definitive Agreement to Receive License Fees of $3M and Royalties of 2% on Future Revenues

ABVC BioPharma Receives Australian Patent, Valid Until 2040, for Its Treatment of Major Depressive Disorder (MDD)

Feb 12, 2024, 8:30 AM EST - 1 year ago

ABVC BioPharma Receives Australian Patent, Valid Until 2040, for Its Treatment of Major Depressive Disorder (MDD)

ABVC Acquires $2.96 Million Worth of Land in Asia with Stocks Priced at $3.50 per Share

Feb 8, 2024, 9:17 AM EST - 1 year ago

ABVC Acquires $2.96 Million Worth of Land in Asia with Stocks Priced at $3.50 per Share

ABVC BioPharma and its Subsidiary Receive $460M From AiBtl BioPharma as the First Milestone Payment of Global Licensing Fees

Jan 3, 2024, 7:24 AM EST - 1 year ago

ABVC BioPharma and its Subsidiary Receive $460M From AiBtl BioPharma as the First Milestone Payment of Global Licensing Fees

ABVC BioPharma Announces Completion of Subject Treatment for Interim Analysis on ADHD Phase IIb Clinical Study

Dec 7, 2023, 8:30 AM EST - 1 year ago

ABVC BioPharma Announces Completion of Subject Treatment for Interim Analysis on ADHD Phase IIb Clinical Study

ABVC BioPharma Receives U.S. Patent for ADHD Treatment, a $32 Billion Market

Nov 21, 2023, 8:30 AM EST - 1 year ago

ABVC BioPharma Receives U.S. Patent for ADHD Treatment, a $32 Billion Market

ABVC BioPharma Enters Definitive Agreement with Licensing Income Worth $467M and Royalties Up to $200M

Nov 16, 2023, 10:05 AM EST - 1 year ago

ABVC BioPharma Enters Definitive Agreement with Licensing Income Worth $467M and Royalties Up to $200M

ABVC BioPharma Reports Third Quarter 2023 Financial and Operational Results

Nov 15, 2023, 9:00 AM EST - 1 year ago

ABVC BioPharma Reports Third Quarter 2023 Financial and Operational Results

ABVC BioPharma Entered Into a Term Sheet to License Global Rights of CNS Drugs with the Indications of MDD and ADHD to AiBtl BioPharma at the Valuation of $667 Million

Oct 26, 2023, 8:30 AM EDT - 1 year ago

ABVC BioPharma Entered Into a Term Sheet to License Global Rights of CNS Drugs with the Indications of MDD and ADHD to AiBtl BioPharma at the Valuation of $667 Million

ABVC BioPharma Announces Completion of Subject Recruitment for Interim Analysis on ADHD Phase IIb Clinical Study

Oct 17, 2023, 8:30 AM EDT - 1 year ago

ABVC BioPharma Announces Completion of Subject Recruitment for Interim Analysis on ADHD Phase IIb Clinical Study

ABVC BioPharma Receives Taiwanese Patent for Its Treatment of Major Depressive Disorder (MDD)

Oct 9, 2023, 8:30 AM EDT - 1 year ago

ABVC BioPharma Receives Taiwanese Patent for Its Treatment of Major Depressive Disorder (MDD)

ABVC BioPharma Provides Updates on ADHD Phase IIb Clinical Study

Aug 23, 2023, 8:30 AM EDT - 1 year ago

ABVC BioPharma Provides Updates on ADHD Phase IIb Clinical Study

ABVC Executes Cooperation Agreement for Strategic Investments

Aug 17, 2023, 9:19 AM EDT - 1 year ago

ABVC Executes Cooperation Agreement for Strategic Investments

ABVC BioPharma Regains Compliance With Nasdaq's Minimum Bid Price Requirement

Aug 10, 2023, 8:30 AM EDT - 1 year ago

ABVC BioPharma Regains Compliance With Nasdaq's Minimum Bid Price Requirement

ABVC Corporate Update and CEO's Letter to Shareholders

Aug 7, 2023, 8:30 AM EDT - 1 year ago

ABVC Corporate Update and CEO's Letter to Shareholders

ABVC Announces the Approval of the Plan for GMP Production Facilities of Vitargus by Taiwan Science Park Administration

Aug 3, 2023, 9:20 AM EDT - 1 year ago

ABVC Announces the Approval of the Plan for GMP Production Facilities of Vitargus by Taiwan Science Park Administration

ABVC Signs a Term Sheet to Earn Licensing Fees of up to $20M and Royalties of 5-12% of Net Sales

Aug 1, 2023, 8:30 AM EDT - 1 year ago

ABVC Signs a Term Sheet to Earn Licensing Fees of up to $20M and Royalties of 5-12% of Net Sales

ABVC BioPharma Announces Closing on $1.75 Million Registered Direct Offering

Jul 31, 2023, 9:30 AM EDT - 1 year ago

ABVC BioPharma Announces Closing on $1.75 Million Registered Direct Offering

ABVC BioPharma Announces Pricing of $1.75 Million Registered Direct Offering

Jul 27, 2023, 9:22 AM EDT - 1 year ago

ABVC BioPharma Announces Pricing of $1.75 Million Registered Direct Offering

ABVC Signs Term Sheet to Acquire Real Estate Assets for Strategic Investments

Jul 26, 2023, 8:30 AM EDT - 1 year ago

ABVC Signs Term Sheet to Acquire Real Estate Assets for Strategic Investments

ABVC BioPharma Announces Reverse Stock Split

Jul 24, 2023, 12:30 PM EDT - 1 year ago

ABVC BioPharma Announces Reverse Stock Split

The New CEO of ABVC BioPharma Takes Steps to Help Improve Cash Efficiency

Jul 6, 2023, 8:30 AM EDT - 1 year ago

The New CEO of ABVC BioPharma Takes Steps to Help Improve Cash Efficiency

ABVC BioPharma, Inc. Announces New CEO as It Targets Further Growth

Jun 26, 2023, 8:30 AM EDT - 1 year ago

ABVC BioPharma, Inc. Announces New CEO as It Targets Further Growth

ABVC BioPharma Subsidiary BioKey Projects $1.0 Million Proceeds From Dietary Supplement Production

Jun 20, 2023, 8:30 AM EDT - 1 year ago

ABVC BioPharma Subsidiary BioKey Projects $1.0 Million Proceeds From Dietary Supplement Production

ABVC BioPharma ADHD Phase II Part 2 Clinical Study First Subject Enrolled at UCSF

Jun 12, 2023, 8:30 AM EDT - 1 year ago

ABVC BioPharma ADHD Phase II Part 2 Clinical Study First Subject Enrolled at UCSF

ABVC BioPharma Announces Collaboration With MerDury BioPharma for New Product Development and Commercialization

Jun 6, 2023, 8:30 AM EDT - 1 year ago

ABVC BioPharma Announces Collaboration With MerDury BioPharma for New Product Development and Commercialization

ABVC BioPharma Vitargus® Phase II Study Received Ethical Approval at Sydney Eye Hospital in Australia

May 22, 2023, 8:30 AM EDT - 1 year ago

ABVC BioPharma Vitargus® Phase II Study Received Ethical Approval at Sydney Eye Hospital in Australia

ABVC BioPharma Provides ABV-1601 Update on Phase I Site Initiation Visit Conducted at Cedars-Sinai Medical Center (CSMC)

Apr 10, 2023, 8:30 AM EDT - 1 year ago

ABVC BioPharma Provides ABV-1601 Update on Phase I Site Initiation Visit Conducted at Cedars-Sinai Medical Center (CSMC)

ABVC BioPharma Provides Vitargus Update on Phase II Site Initiation Visit Conducted at Ramathibodi Hospital in Thailand

Apr 6, 2023, 8:30 AM EDT - 1 year ago

ABVC BioPharma Provides Vitargus Update on Phase II Site Initiation Visit Conducted at Ramathibodi Hospital in Thailand

ABVC BioPharma Announces Fiscal Year 2022 Financial and Operational Results

Mar 31, 2023, 6:49 PM EDT - 1 year ago

ABVC BioPharma Announces Fiscal Year 2022 Financial and Operational Results

ABVC BioPharma Provides Vitargus® Update on Phase II Site Initiation Visit Conducted at Srinagarind Hospital in Thailand

Mar 20, 2023, 7:00 AM EDT - 1 year ago

ABVC BioPharma Provides Vitargus® Update on Phase II Site Initiation Visit Conducted at Srinagarind Hospital in Thailand

ABVC BioPharma Receives Registration Approval for Maitake Mushroom Dietary Supplement by the Taiwan Ministry of Health and Welfare

Mar 14, 2023, 7:00 AM EDT - 2 years ago

ABVC BioPharma Receives Registration Approval for Maitake Mushroom Dietary Supplement by the Taiwan Ministry of Health and Welfare

ABVC BioPharma Provides 2023 Pipeline Update

Feb 28, 2023, 8:30 AM EST - 2 years ago

ABVC BioPharma Provides 2023 Pipeline Update

ABVC BioPharma Receives $3.175 Million Investment From The Lind Partners to Continue Clinical Trials

Feb 23, 2023, 4:16 PM EST - 2 years ago

ABVC BioPharma Receives $3.175 Million Investment From The Lind Partners to Continue Clinical Trials

ABVC BioPharma Receives Australian TGA Approval to Initiate Phase II Study of Vitargus®

Feb 21, 2023, 8:30 AM EST - 2 years ago

ABVC BioPharma Receives Australian TGA Approval to Initiate Phase II Study of Vitargus®

ABVC BioPharma ABV-1505 ADHD Phase IIa Results Presented at 2023 APSARD Conference

Jan 19, 2023, 8:30 AM EST - 2 years ago

ABVC BioPharma ABV-1505 ADHD Phase IIa Results Presented at 2023 APSARD Conference

FDA Approves IND Submission Allowing ABVC BioPharma to Proceed With Clinical Study of ABV-1519 for Treatment of Non-Small Cell Lung Cancer

Jan 5, 2023, 8:30 AM EST - 2 years ago

FDA Approves IND Submission Allowing ABVC BioPharma to Proceed With Clinical Study of ABV-1519 for Treatment of Non-Small Cell Lung Cancer

ABVC BioPharma Provides Vitargus® Update - Phase II Vitargus® Study Protocol Received Thai FDA Approval

Nov 17, 2022, 8:30 AM EST - 2 years ago

ABVC BioPharma Provides Vitargus® Update - Phase II Vitargus® Study Protocol Received Thai FDA Approval

ABVC BioPharma Reports Third Quarter 2022 Financial and Operational Results

Nov 14, 2022, 6:20 PM EST - 2 years ago

ABVC BioPharma Reports Third Quarter 2022 Financial and Operational Results

ABVC BioPharma Receives Notice of Allowance from US Patent and Trademark Office for ABV-1504 Used to Treat Major Depressive Disorder (MDD)

Nov 7, 2022, 8:30 AM EST - 2 years ago

ABVC BioPharma Receives Notice of Allowance from US Patent and Trademark Office for ABV-1504 Used to Treat Major Depressive Disorder (MDD)

Cedars-Sinai Medical Center Joins Phase I Clinical Study of ABVC BioPharma's Medication for Treating Depression in Cancer Patients

Nov 2, 2022, 8:30 AM EDT - 2 years ago

Cedars-Sinai Medical Center Joins Phase I Clinical Study of ABVC BioPharma's Medication for Treating Depression in Cancer Patients